FDA grants breakthrough designation for new AI model to detect cardiac amyloidosis in ECG results
Related Articles
Philips Launches ECG-AI Marketplace to Enhance Early Cardiac Diagnosis
Anumana's FDA-cleared LEF algorithm becomes first certified third-party solution available through Philips’ ECG ecosystemJuly 17, 2025
Pfizer and Anumana boost detection of cardiovascular disease
Pharma Times: Artificial intelligence (AI) health technology company, Anumana, will collaborate with Pfizer to develop an artificial intelligence electrocardiogram algorithm (AI-ECG), which enables the early detection of cardiac amyloidosis.December 16, 2022
Building sEHR-BERT: A Custom Language Model for Structured Electronic Health Records – Adapting transformer architecture for the unique challenges of medical coding and structured health data
Why Standard BERT Isn't Enough for Structured EHRs BERT revolutionized natural language processing, but electronic health records (EHRs) present unique challenges that standard language models weren't designed to handle. While BERT…January 22, 2026
Anumana & Pfizer Partner on Amyloidosis AI-ECG Algorithm Development
HIT Consultant: Anumana, an AI-driven health technology company and portfolio company of nference, today announced a multi-year agreement with Pfizer for Anumana to develop an investigational artificial intelligence electrocardiogram algorithm…December 16, 2022